MY157192A - Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine receptor ligands - Google Patents
Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine receptor ligandsInfo
- Publication number
- MY157192A MY157192A MYPI2010000523A MYPI20100523A MY157192A MY 157192 A MY157192 A MY 157192A MY PI2010000523 A MYPI2010000523 A MY PI2010000523A MY PI20100523 A MYPI20100523 A MY PI20100523A MY 157192 A MY157192 A MY 157192A
- Authority
- MY
- Malaysia
- Prior art keywords
- receptor ligands
- dopamine receptor
- methods
- pharmaceutical compositions
- compositions containing
- Prior art date
Links
- 102000015554 Dopamine receptor Human genes 0.000 title abstract 5
- 108050004812 Dopamine receptor Proteins 0.000 title abstract 5
- 239000003446 ligand Substances 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 abstract 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 abstract 2
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 208000028683 bipolar I disease Diseases 0.000 abstract 1
- 208000025307 bipolar depression Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000024714 major depressive disease Diseases 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Addiction (AREA)
- Pregnancy & Childbirth (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95369407P | 2007-08-03 | 2007-08-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY157192A true MY157192A (en) | 2016-05-13 |
Family
ID=40338740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2010000523A MY157192A (en) | 2007-08-03 | 2008-08-04 | Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine receptor ligands |
Country Status (20)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101612146B1 (ko) | 2008-07-16 | 2016-04-12 | 리히터 게데온 닐트. | 도파민 수용체 리간드를 함유하는 약학적 제형 |
| US20110117214A1 (en) * | 2009-11-16 | 2011-05-19 | Auspex Pharmaceuticals, Inc. | Cyclohexyl urea modulators of d2 receptors and/or d3 receptors |
| LT2582701T (lt) * | 2010-06-18 | 2017-03-27 | Altos Therapeutics, LLC | D2 antagonistai, sintezės būdai ir panaudojimo būdai |
| WO2014031162A1 (en) | 2012-08-20 | 2014-02-27 | Forest Laboratories Holdings Limited | Crystalline form of carbamoyl-cyclohexane derivatives |
| US11274087B2 (en) | 2016-07-08 | 2022-03-15 | Richter Gedeon Nyrt. | Industrial process for the preparation of cariprazine |
| HUP1700253A1 (hu) * | 2017-06-13 | 2019-01-28 | Richter Gedeon Nyrt | Szilárd orális gyógyszerkészítmények |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| US12459965B2 (en) | 2017-10-09 | 2025-11-04 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| HU231500B1 (hu) | 2019-04-10 | 2024-04-28 | Richter Gedeon Nyrt | Karbamoil-ciklohexán származékok autizmus spektrum betegség kezelésére |
| US11547707B2 (en) | 2019-04-10 | 2023-01-10 | Richter Gedeon Nyrt. | Carbamoyl cyclohexane derivatives for treating autism spectrum disorder |
| KR20220009954A (ko) | 2019-04-17 | 2022-01-25 | 컴퍼스 패쓰파인더 리미티드 | 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법 |
| JP2024537491A (ja) * | 2021-10-28 | 2024-10-10 | アッヴィ・インコーポレイテッド | 大うつ病性障害の治療 |
| AU2022409230A1 (en) * | 2021-12-13 | 2024-06-20 | Compass Pathfinder Limited | Psilocybin and an adjunctive serotonin reuptake inhibitor for use in the treatment of treatment-resistant depression |
| EP4493274A1 (en) * | 2022-03-17 | 2025-01-22 | Mapi Pharma Ltd. | Depot systems comprising cariprazine or salts thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8814057D0 (en) * | 1988-06-14 | 1988-07-20 | Lundbeck & Co As H | New enantiomers & their isolation |
| ZA977967B (en) * | 1996-09-23 | 1999-03-04 | Lilly Co Eli | Combination therapy for treatment of psychoses |
| US6960577B2 (en) * | 1998-05-22 | 2005-11-01 | Eli Lilly And Company | Combination therapy for treatment of refractory depression |
| US6556540B1 (en) * | 1998-05-29 | 2003-04-29 | Paradyne Corporation | System and method for non-intrusive measurement of service quality in a communications network |
| PT1298124E (pt) * | 1999-10-25 | 2007-05-31 | Lundbeck & Co As H | Método para a preparação de citalopram |
| UA77650C2 (en) * | 1999-12-06 | 2007-01-15 | Lundbeck & Co As H | Use of serotonin reuptake inhibitor in combination with deramcyclane |
| CZ20033267A3 (en) * | 2001-05-01 | 2004-06-16 | H. Lundbeck A/S | The use of enantiomeric pure escitalopram |
| WO2003086393A1 (en) * | 2002-04-12 | 2003-10-23 | Sepracor, Inc. | 3-aza- and 1,4-diaza-bicyclo[4.3.0]nonanes, and methods of use thereof |
| KR20050012284A (ko) * | 2002-06-20 | 2005-01-31 | 하. 룬트벡 아크티에 셀스카브 | 세로토닌 재흡수 저해제가 사용되는 병용 치료법 |
| HU227534B1 (en) * | 2003-08-04 | 2011-08-29 | Richter Gedeon Nyrt | (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them |
| US20070042014A1 (en) * | 2003-09-04 | 2007-02-22 | H. Lundbeck A/S | Combination of a serotonin reuptake inhibitor and loxapine |
| HUP0500170A3 (en) * | 2005-02-03 | 2007-11-28 | Richter Gedeon Nyrt | Piperazine derivatives, process for producing them and pharmaceutical compositions containing them |
| TW200812993A (en) * | 2006-05-02 | 2008-03-16 | Lundbeck & Co As H | New uses of escitalopram |
| HU230748B1 (hu) * | 2007-05-11 | 2018-02-28 | Richter Gedeon Nyrt | Új piperazin só és előállítási eljárása |
-
2008
- 2008-08-04 MY MYPI2010000523A patent/MY157192A/en unknown
- 2008-08-04 CN CN2008801062563A patent/CN101815519B/zh active Active
- 2008-08-04 EA EA201000280A patent/EA018064B1/ru unknown
- 2008-08-04 KR KR1020107004638A patent/KR101612563B1/ko active Active
- 2008-08-04 JP JP2010520238A patent/JP5460594B2/ja active Active
- 2008-08-04 NO NO08782602A patent/NO2185155T3/no unknown
- 2008-08-04 HU HUE08782602A patent/HUE036004T2/hu unknown
- 2008-08-04 AU AU2008283989A patent/AU2008283989B2/en active Active
- 2008-08-04 SI SI200831900T patent/SI2185155T1/en unknown
- 2008-08-04 LT LTEP08782602.0T patent/LT2185155T/lt unknown
- 2008-08-04 ES ES08782602.0T patent/ES2653852T3/es active Active
- 2008-08-04 US US12/185,211 patent/US20090036468A1/en not_active Abandoned
- 2008-08-04 WO PCT/US2008/072066 patent/WO2009020897A1/en not_active Ceased
- 2008-08-04 CA CA2695519A patent/CA2695519A1/en not_active Abandoned
- 2008-08-04 EP EP08782602.0A patent/EP2185155B1/en active Active
- 2008-08-04 DK DK08782602.0T patent/DK2185155T3/en active
- 2008-08-04 PL PL08782602T patent/PL2185155T3/pl unknown
- 2008-08-04 PT PT87826020T patent/PT2185155T/pt unknown
- 2008-08-04 HR HRP20171908TT patent/HRP20171908T1/hr unknown
-
2010
- 2010-09-27 US US12/890,752 patent/US20110015208A1/en not_active Abandoned
-
2011
- 2011-10-10 US US13/269,928 patent/US20120028991A1/en not_active Abandoned
-
2017
- 2017-12-07 CY CY20171101293T patent/CY1119828T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN101815519A (zh) | 2010-08-25 |
| EA201000280A1 (ru) | 2010-08-30 |
| HUE036004T2 (hu) | 2018-06-28 |
| HRP20171908T1 (hr) | 2018-01-26 |
| CN101815519B (zh) | 2013-08-21 |
| WO2009020897A1 (en) | 2009-02-12 |
| KR20100059830A (ko) | 2010-06-04 |
| EP2185155A1 (en) | 2010-05-19 |
| ES2653852T3 (es) | 2018-02-09 |
| AU2008283989B2 (en) | 2013-12-05 |
| KR101612563B1 (ko) | 2016-04-14 |
| EP2185155B1 (en) | 2017-10-04 |
| CA2695519A1 (en) | 2009-02-12 |
| US20120028991A1 (en) | 2012-02-02 |
| SI2185155T1 (en) | 2018-02-28 |
| NO2185155T3 (cg-RX-API-DMAC7.html) | 2018-03-03 |
| US20110015208A1 (en) | 2011-01-20 |
| JP5460594B2 (ja) | 2014-04-02 |
| HK1144784A1 (en) | 2011-03-11 |
| AU2008283989A1 (en) | 2009-02-12 |
| US20090036468A1 (en) | 2009-02-05 |
| JP2010535790A (ja) | 2010-11-25 |
| EA018064B1 (ru) | 2013-05-30 |
| DK2185155T3 (en) | 2018-01-02 |
| PL2185155T3 (pl) | 2018-03-30 |
| PT2185155T (pt) | 2018-01-04 |
| LT2185155T (lt) | 2017-12-11 |
| CY1119828T1 (el) | 2018-06-27 |
| EP2185155A4 (en) | 2012-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY157192A (en) | Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine receptor ligands | |
| EA201001329A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| TN2010000122A1 (en) | Compounds and compositions as modulators of gpr119 activity | |
| MX2009009491A (es) | Compuestos y composiciones como moduladores de la actividad del gpr119. | |
| EA201100138A1 (ru) | 4-феноксиметилпиперидины в качестве модуляторов активности gpr119 | |
| EA200901032A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| EA201001332A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| UA99936C2 (en) | Biaryl substituted azabicyclic alkane derivatives | |
| EA201001330A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| EA201200570A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| UA99882C2 (uk) | Похідні бензофуранілу, фармацевтична композиція та спосіб лікування захворювань (варіанти) | |
| EA201071089A1 (ru) | Производные хиназолина как модуляторы raf-киназы и способы их применения | |
| MX2009012787A (es) | Nuevas fenilpirrolidinas disustituidas como moduladores de neurotransmision catecolaminergica cortical. | |
| EA201001639A1 (ru) | Композиции и способы их получения и применения | |
| PH12013502240B1 (en) | Novel compounds as modulators of protein kinase | |
| MX2009010984A (es) | Moduladores de heterociclo cinasa de anillo fusionado. | |
| MX2009010207A (es) | Peptidos de hidrazido como inhibidores de proteasa ns3 de virus de hepatitis c. | |
| EA200970967A1 (ru) | Оксадиазол замещенные производные индазола для применения в качестве агонистов сфингозин 1-фосфата (sip) | |
| MX368459B (es) | Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central. | |
| EA201170356A1 (ru) | Полиморфные и аморфные формы лакозамида и аморфные композиции | |
| MX2011010918A (es) | Metodo para el tratamiento de trastornos asociados con la actividad de la cinasa de proteina ck2. | |
| MY164998A (en) | Isoquinolinone derivatives as nk3 antagonists | |
| MX2010009147A (es) | Derivados de pirrolidinilo y usos de los mismos. | |
| GB201213484D0 (en) | Pharmaceutical compositions comprising 15-OHEPA and methods of using the same | |
| UA104152C2 (ru) | Производные 3-фенил-3-метоксипирролидина, как модуляторы кортикальной катехоламинергической нейротрансмиссии |